Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-09-16
2010-12-28
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S368000
Reexamination Certificate
active
07858630
ABSTRACT:
The present invention provides compounds of the general formula (I)wherein X, n and R1are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT2aand dopamine D3receptors, useful in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
REFERENCES:
patent: WO 95/11680 (1995-05-01), None
patent: WO 02/066446 (2002-08-01), None
patent: WO 2004/026864 (2004-04-01), None
patent: WO 2004/100954 (2004-11-01), None
patent: WO 2004/100955 (2004-11-01), None
patent: WO 2007/093540 (2007-08-01), None
patent: WO 2009/013212 (2009-01-01), None
Roth et al., Nat. Rev. Drug. Discovery vol. 3 pp. 353-359 (2004).
Lieberman et al., N. Engl. J. Med. vol. 353, pp. 1209-1223 (2005).
Missale et al., Physiol. Rev. vol. 78 pp. 189-225 (1998).
Gurevich E. V., Neuropsychopharmacology vol. 20 pp. 60-80 (1999).
Joyce J. N., Drug Discovery Today 1, vol. 10, No. 13 pp. 917-925 (2005).
Gurevich E.V., Arch. Gen. Psychiatry vol. 54 pp. 225-232 (1997).
Leikin et al., Med. Toxicol. Adverse Drug Exp. vol. 4 pp. 324-350 (1989).
Harrison P. J., Br. J. Psychiatry Suppl. 38 pp. 12-22 (1999).
Barnes N. M., Neuropharmacology vol. 38 pp. 1083-1152 (1999).
Pompeiano et al., Brain Res. Mol. vol. 23 pp. 163-178 (1994).
Roth et al., Pharmacol. Ther. vol. 79 pp. 231-257 (1998).
Spurlock et al., Mol. Psychiatry vol. 3 pp. 42-49 (1998).
Arranz et al., Lancet vol. 355 pp. 1615-1616 (2000).
Porras et al., Neuropsychopharmacology vol. 26 pp. 311-324 (2002).
De Angelis L., Curr. Opin. Investig. Drugs. vol. 3 pp. 106-112 (2002).
Meltzer et al., J. Pharmacol. Exp. Ther. vol. 251 pp. 238-246 (1989).
Wustrow, et al., Journal of Medicinal Chemistry vol. 41 pp. 760-771 (1998).
Pazos et al., (1987), Neuroscience, pp. 123-139.
Reavill et al., (2000), JPET vol. 294, pp. 1154-1165.
Millan, M. J. (2005), Drug Discovery Today, pp. 917-925.
Vovel et al. (2002) J. Neurosci. vol. 22, pp. 9595-9603.
Campos et al. (2003) Soc. Neurosci. Abstr. 322.8.
Ashby (2003) Synapse vol. 48 pp. 154-156.
Dresher K. (2002) Am. Soc. Neurosci. Abstr. 894.6.
Gobbi Luca
Jaeschke Georg
Rodriguez Sarmiento Rosa Maria
Steward Lucinda
Bernhardt Emily
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
D 3 and 5-HT 2A receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with D 3 and 5-HT 2A receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and D 3 and 5-HT 2A receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237936